D. E. Shaw & Co., Inc. Alx Oncology Holdings Inc Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 18,940 shares of ALXO stock, worth $28,978. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,940

Holding current value

$28,978

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $110,609 - $332,586	18,940 New	18,940 $114,000
Q4 2023 Feb 14, 2024	BUY	$4.81 - $15.38 $21,625 - $69,148	4,496 Added 9.84%	50,178 $747,000
Q3 2023 Nov 14, 2023	SELL	$4.19 - $7.35 $10,579 - $18,558	-2,525 Reduced 5.24%	45,682 $219,000
Q2 2023 Aug 14, 2023	BUY	$4.37 - $9.56 $31,166 - $68,181	7,132 Added 17.36%	48,207 $362,000
Q1 2023 May 15, 2023	BUY	$4.52 - $11.71 $68,487 - $177,429	15,152 Added 58.45%	41,075 $185,000
Q4 2022 Feb 14, 2023	BUY	$9.51 - $12.95 $6,657 - $9,065	700 Added 2.78%	25,923 $292,000
Q3 2022 Nov 14, 2022	SELL	$8.23 - $15.14 $75,411 - $138,727	-9,163 Reduced 26.65%	25,223 $241,000
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $202,533 - $669,151	34,386 New	34,386 $278,000
Q4 2021 Feb 14, 2022	SELL	$21.49 - $74.4 $165,687 - $573,624	-7,710 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$52.51 - $80.91 $2 Million - $3.08 Million	-38,109 Reduced 83.17%	7,710 $569,000
Q2 2021 Aug 16, 2021	SELL	$52.2 - $75.23 $336,115 - $484,405	-6,439 Reduced 12.32%	45,819 $2.51 Million
Q1 2021 May 17, 2021	BUY	$62.84 - $87.68 $2.85 Million - $3.98 Million	45,423 Added 664.56%	52,258 $3.85 Million
Q4 2020 Feb 16, 2021	BUY	$34.11 - $112.26 $233,141 - $767,297	6,835 New	6,835 $589,000

Others Institutions Holding ALXO

# of Institutions

116

Shares Held

41M

Call Options Held

518K

Put Options Held

142K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $62.3M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account